MedPath
FDA Approval

Eptifibatide

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
July 25, 2021
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Eptifibatide(0.75 mg in 1 mL)

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Gland Pharma Limited

Amneal Pharmaceuticals LLC

918601238

Products2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Eptifibatide

Product Details

NDC Product Code
70121-1003
Application Number
ANDA205581
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
July 25, 2021
Code: NA8320J834Class: ACTIBQuantity: 0.75 mg in 1 mL
CITRIC ACID MONOHYDRATEInactive
Code: 2968PHW8QPClass: IACTQuantity: 5.25 mg in 1 mL
SODIUM HYDROXIDEInactive
Code: 55X04QC32IClass: IACT
WATERInactive
Code: 059QF0KO0RClass: IACT

Eptifibatide

Product Details

NDC Product Code
70121-1002
Application Number
ANDA205581
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
July 25, 2021
Code: NA8320J834Class: ACTIBQuantity: 2 mg in 1 mL
WATERInactive
Code: 059QF0KO0RClass: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32IClass: IACT
CITRIC ACID MONOHYDRATEInactive
Code: 2968PHW8QPClass: IACTQuantity: 5.25 mg in 1 mL
© Copyright 2025. All Rights Reserved by MedPath